News

A dual-action vaccine that can both kill and prevent cancer has been trialed in mouse models of glioblastoma, with promising results.

Researchers have designed and synthesized analogs of a new antibiotic that is effective against multidrug-resistant bacteria, opening a new front in the fight against these infections.

People with a blistering skin disease called dystrophic epidermolysis bullosa often suffer from large open wounds that last for years or decades. A double-blind, placebo-controlled clinical trial of a gene therapy gel developed at Stanford Medicine shows improved wound healing in people with the disease.

A new personalized cancer vaccine has demonstrated efficacy against melanoma in a Phase IIb clinical trial.

Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups.

A new study from Weill Cornell Medicine has noted that the long-term immune response to the SARS-CoV-2 mRNA vaccine is similar in pregnant and non-pregnant individuals.

Researchers have identified specific bacteria in the bladder that may indicate which postmenopausal women are more susceptible to recurrent urinary tract infections (UTIs), and they found that estrogen may play a role in reducing that susceptibility.

Researchers describe using RNA-targeting CRISPR/Cas13d technology to develop a new therapeutic strategy that specifically eliminates toxic RNA that causes Huntington's disease.

A new immunotherapy has proven successful in 73% of multiple myeloma (MM) cancer patients in a Phase II clinical trial.

According to research, reprogramming cells to promote hair cell regeneration in mature animals could lead to long-term hearing loss treatment.